NICE approves brain cancer drug following change to cost-effectiveness thresholds

Vorasidenib, a daily pill, has been approved for people aged over 12 years who have astrocytoma or oligodendroglioma with isocitrate dehydrogenase IDH1 or IDH2 mutations.…